Lung Cancer: First-Line Treatment of M7824 Versus PembrolizumabResearch Question:
What is the effect of M7824 monotherapy versus pembrolizumab as 1L treatment for participants
with advanced NSCLC with high PD-L1-tumor expression?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The study will evaluate M7824 monotherapy versus pembrolizumab as first-line treatment
for participants with advanced non-small-cell lung carcinoma (NSCLC) with high PD-L1-tumor
expression (PD-L1 stand for Programmed Death-Ligand 1).
Study Reference #: ILUN18120
Lead Researcher (Principal Investigator)
Deborah Mulford, MD
Study Contact InformationStudy Coordinator: Amy Jasek
Phone: (585) 273-1912
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search